Osteoporosis Drugs Market To Attain USD 10.47 Billion By 2026, Showcasing A 3.9% CAGR

According to the report, the global osteoporosis drugs industry was estimated at $7.65 billion in 2018, and is expected to hit $10.47 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.

In detail along with the table of contents, please click on the link below:

https://www.alliedmarketresearch.com/request-sample/1491

Based on drug class, the bisphosphonates segment held more than one-third of the total market share in 2018, and is estimated to maintain its largest share in terms of revenue throughout the forecast period. However, the rank ligand inhibitors segment is estimated to witness the highest CAGR of 8.6% from 2019 to 2026. The report also analyzes segments including selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, and others.

Based on route of administration, the oral segment accounted for nearly three-fifths of the total share in 2018, and is estimated to maintain its lead status throughout the forecast period. However, the injectable segment is estimated to portray the largest growth rate with a CAGR of 4.4% from 2019 to 2026.

The oral segment to maintain the lion's share during the estimated period-

Based on route of administration, the oral segment held the major share in 2018, garnering nearly three-fifths of the global osteoporosis drugs market, owing to the large number of osteoporosis medications, which are available as oral drugs in the market. Simultaneously, the injectable segment would manifest the CAGR of 4.4% throughout the forecast period, owing to factors such as rise in need for drugs, which exhibit enhanced bioavailability and act rapidly

North America to lead the trail till 2026-

Based on region, North America accounted for nearly half of the global osteoporosis drugs market share in 2018, and is projected to rule the roost during the study period. Owing to easy availability of osteoporosis drugs and surge in incidence of osteoporosis. At the same time, the LAMEA region would portray the fastest CAGR of 5.5% by 2026. This is attributed to increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. In addition, the constantly evolving life science industry fuels the growth of the market in the developing economies such as India, China, and Malaysia.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1491

The bisphosphonates segment to retain its dominance by 2026-

Based on drug class, the bisphosphonates segment contributed to more than one-third of the global osteoporosis drugs market revenue in 2018 and is expected to dominate from 2019 to 2026. This is owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players. On the other hand, the rank ligand inhibitors would cite the fastest CAGR of 8.6% by the end of 2026, owing to the fact that these drugs are used to treat bone metastasis by acting as a chemo attractant to bone for tumor cells that expresses its receptor, RANK.

Key market players-

Amgen Inc.
F. Hoffmann-La Roche AG
Radius Health
Merck & Co. Inc.
Novartis International AG (Sandoz)
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Allied Market Research Coverage on the Healthcare Domain:

Gastrointestinal Therapeutics Market https://www.alliedmarketresearch.com/gastrointestinal-therapeutics-market

Cath Lab Services market https://www.alliedmarketresearch.com/cath-lab-market-A11508

Portable Dental Chair Market https://www.alliedmarketresearch.com/portable-dental-chair-market-A214060

Contact Data:

David Correa

1209 Orange Street, Corporation Trust Center, Wilmington, New Castle, Delaware 19801 USA.

Toll Free: +1-800-792-5285| Int'l: +1-503-894-6022

UK: +44-845-528-1300| Hong Kong: +852-301-84916

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.